July 24 (Reuters) - Essa Pharma Inc EPI.TO
* Says additional data is currently being received from higher dose cohorts in Phase 1 clinical trial of EPI-506
* Says intends to delay an offering until after that data can be announced from ongoing highest dose cohorts
* Says it will provide further updates as they become available